Abstract:Objective To analyze the suspicious results of serum HBV DNA by fluorescence quantitative PCR and develop appropriate countermeasures in order to improve the quality of detection of HBV DNA.Methods Blood samples of patients from the First Affiliated Hospital of Wenzhou Medical College from 2008 to 2011 were analyzed for HBV DNA by fluorescence quantitative PCR.1969 cases of suspicious results,judged by the rule of review the results of serum HBV DNA combined with the historical results,PCR amplification curve,HBV serum markers and clinical diagnosis,were analyzed and redetected by using of two different reagents,careHBV PCR Kit and careHBV PCR Kit V2,at the same time.The consistency and inconsistency ratio of the results were evaluated.Both the reasons of inconsistent and the undetected rates of careHBV PCR Kit were analyzed.The two reasons for the inconsistent results included the reagent related factors,e.g,showing no amplification curve caused by the false negative and abnormal low efficiency of amplification curve,and the non reagent related factors such as operating pollution and other sample factors.Results There were 115 154 blood samples were detected for HBV from 2008 to 2011 and 1969 samples (1.71％) with suspicious results were redetected.The consistency and inconsistency results were 1588 (80.65％) and 381 (19.35％),respectively.Every year from 2008 to 2011,the percentage of the inconsistent results caused by the reagent related factors were 18.87％,20.23％,51.33％ and 59.57％ respectively,which showed an increasing trend,and the percentage of inconsistent results caused by the nonreagent related factors were 81.13％,79.77％,48.67％ and 40.43％ respectively,which showed a declining trend year by year.The undetected rates of careHBV PCR Kit were 2.49％,4.08％,10.09％ and 14.47％ respectively,showing an increasing trend.Conclusions The redetection for the specimens with the suspicious results by using of different reagents can avoid the blind detection of HBV DNA and reduce the experimental error.All the clinical samples for quantitative HBV DNA including the mutations of HBV gene can be measured accurately and effectively,which is helpful to hepatitis B patients for antiviral therapy.

Research on the influence of the different diluents to hepatitis B surface antigen in human serum

Determination of Low Level HBsAg in Serum by Microparticle Enzyme Immunoassay.

[Relationship between the quantitative results of HBV DNA and HBV markers (HBV M) in population with low-level HBsAg].

Determination of Low Level HBsAg in Serum by MEIA

Evaluation of methods for confirming the weak-reactive results of HBsAg in serum

Analysis of suspicious results of serum HBV DNA detected by fluorescence quantitative PCR

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

The Measurement of HBV DNA in peripheral blood mononuclear cells and its clinical applicability

Comparison of the results for three automated immunoassay systems in determining serum HBV markers.

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Comparative analysis of the difference between three methods in detecting HBV serum markers

Comparison study and analysis of detecting HBsAb using ECLIA and ELISA

Evaluation of different methods in determination of low level HBsAg]

Comparative Study of Three Methods and Four HBV Kits for Automatic Detection of HBV Markers in Serum

Sensitivity and specificity of 4 domestic ELISA kits for detection of hepatitis B virus markers

Compare the Relationship Between HBV Immunoiogical Marker and HBV-DNA Concentrations

Establishment of the First Reference Materials for Hepatitis B Surface Antigen Immunoassay

Performance Evaluation of HBsAg by Lumipulse HBsAg-HQ: the Agreement with HBsAg by Architect HBsAg-QT and the Effectiveness in Predicting Liver Tissue Pathological States of Chronic Hepatitis B Patients

Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection